StockData
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. (SPRY) stock

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$3.69+0.04 (+1.10%)

Close on Nov 18, 2026Market cap $366.96MP/E –Yield –

ARS Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

ARS Pharmaceuticals's pe ratio was 171.1× on Apr 30, 2025.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 2025171.1×+160.5
2023Jan 31, 202310.6×−2.6
2022Dec 30, 202213.1×–

More ARS Pharmaceuticals figures

See a number that looks wrong?